Results 41 to 50 of about 7,229 (203)

Medicinal Chemistry Aspects of Thiazole and Thiazolidine Derivatives as Fundamental Building Blocks to Design New NNRTIs Against HIV‐1 Reverse Transcriptase

ChemMedChem, Volume 21, Issue 19, 14 October 2026.
HIV‐1 reverse transcriptase (HIV‐1 RT) is a polymerase enzyme and a key target in HIV‐1 therapy. The discovery of selective HIV‐1 RT inhibitors has highlighted thiazole scaffolds and their derivatives, thiazolidine‐2‐one and thiazolidine‐2,4‐dione, as promising structures for the rational design of novel non‐nucleoside reverse transcriptase inhibitors (
José Arion da Silva Moura, Matheus Vinicius Guimarães de Melo, Diane Regis Santos do Nascimento, Thaynara Paula Warren Bezerra, Mathieu Métifiot, Patricia Recordon‐Pinson, Maira Galdino da Rocha Pitta, Marina Galdino da Rocha Pitta, Michelly Cristiny Pereira, Marie‐Line Andreola   +9 more
wiley   +1 more source

Factors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- and middle-income countries

, 2016
Objectives: The use of the NNRTI rilpivirine in low- and middle-income countries (LMICs) is under debate. The main objective of this study was to provide further clinical insights and biochemical evidence on the usefulness of rilpivirine in LMICs ...
Rao, Shwetha D., Sarafianos, Stefan G., Neogi, Ujjwal, ZAZZI, MAURIZIO, Häggblom, Amanda, Singh, Kamalendra, Arnold, Eddy, Amogne, Wondwossen, Rogers, Leonard C., Schülter, Eugen, Sönnerborg, Anders   +10 more
core   +1 more source

Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2

, 2022
Background: Switching to the 2-drug regimen dolutegravir + rilpivirine demonstrated noninferiority vs continuing a 3-drug or 4-drug current antiretroviral regimen (CAR) at week 48 and maintained high levels of virologic suppression to week 148 in the ...
Aylott, Alicia, Van Solingen-Ristea, Rodica, Matthews, Jessica, Llibre, Josep M., van Wyk, Jean, Wynne, Brian, Kahl, Lesley P., López Cortés, Luis Fernando, Vandermeulen, Kati   +8 more
core   +1 more source

Spectrum of Non-Nucleoside Reverse Transcriptase Inhibitor-Associated Drug Resistance Mutations in Persons Living with HIV-1 Receiving Rilpivirine

Viruses
Introduction: Few data are currently available on the nonnucleoside reverse transcriptase (RT) inhibitors (NNRTI) resistance mutations selected in persons living with HIV-1 (PLWH) who develop virological failure while receiving rilpivirine (RPV). Methods:
Pavithra Nagarajan, Jinru Zhou, Giulia Di Teodoro, Francesca Incardona, Carole Seguin-Devaux, Rolf Kaiser, Ana B. Abecasis, Perpetua Gomes, Kaiming Tao, Maurizio Zazzi, Robert W. Shafer   +10 more
doaj   +1 more source

Characteristics and management of low‐level viraemia in people living with HIV in a resource‐limited setting: A multicentre retrospective study in Greece

HIV Medicine, Volume 27, Issue 10, Page 1663-1669, October 2026.
Abstract Objectives Low‐level viraemia (LLV) persists in some people living with HIV despite antiretroviral therapy, raising concerns about virologic failure. We assessed the characteristics, management and outcomes of LLV in Greece, where next‐generation sequencing, therapeutic drug monitoring and electronic adherence monitoring are unavailable ...
Lydia Leonidou, Giota Lourida, Konstantinos Protopapas, Charalampos D. Moschopoulos, Dimitrios Zoulas, Charisis Totsikas, Dimitrios Basoulis, Elpida Mastrogianni, Apostolos Beloukas, Maria Lagadinou, Markos Marangos, Vasileios Papastamopoulos, Antonios Papadopoulos, Mina Psichogiou   +13 more
wiley   +1 more source

Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir

HIV/AIDS: Research and Palliative Care, 2013
Mark A WainbergMcGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, CanadaAbstract: A recent addition to the anti-human immunodeficiency virus armamentarium of drugs is rilpivirine, which is a potent non ...
Wainberg MA
doaj  

Real-World Experience with Long-Acting Injectable Cabotegravir/Rilpivirine in HIV Patients with Unsuppressed Viral Load

Viruses
Long-acting injectable cabotegravir/rilpivirine (CAB/RPV-LA) is currently approved as a maintenance therapy for people with HIV (PWH) who are virologically suppressed.
Marcello Trizzino, Luca Pipitò, Pierluigi Francesco Salvo, Federica Zimmerhofer, Andrea Cicero, Gianmaria Baldin, Claudia Conti, Claudia Gioè, Simona Di Giambenedetto, Antonio Cascio   +9 more
doaj   +1 more source

Dolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected patients in a clinical setting

HIV Research & Clinical Practice, 2019
Objectives: There are scarce data on the combination of dolutegravir (DTG) plus rilpivirine (RPV) in the real world, including patients with hepatitis C virus (HCV) coinfection, toxicity or previous failure, or at risk for severe drug–drug interactions ...
Jose L. Casado, Marta Monsalvo, María Fontecha, Pilar Vizcarra, Miguel A Rodriguez, María Jesús Vivancos, Santiago Moreno   +6 more
doaj   +1 more source

ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS DETERMINATION OF CABOTEGRAVIR AND RILPIVIRINE USING RP-HPLC [PDF]

Bulletin of Pharmaceutical Sciences. Assiut University
Type I HIV can be treated by the combination of these drugs. An accurate, precise, and novel RP-HPLC technique was developed and validated for concurrent assessment of cabotegravir and rilpivirine in bulk and medicinal formulation.
Sahitya Bharathi Chodimella, Raja Sundararajan   +1 more
doaj   +1 more source

Making the Case for Organ‐on‐Chip Platforms in Long‐Acting Therapeutics Development

Advanced Healthcare Materials, Volume 15, Issue 36, 25 September 2026.
LATs release drug from a tissue‐resident depot over weeks to months, improving adherence, but their development is hampered by preclinical models that cannot reproduce the coupled tissue processes, sustained release, local microenvironment change, interstitial transport, immune and foreign‐body responses, and clearance that govern depot performance in ...
Charlie Gowans, Abdulwahhab Khedr, Panagiotis G. Georgiou, Nehir Arik, Ozlem Sen, Steve P. Rannard, Tom O. McDonald, Christos Tapeinos   +7 more
wiley   +1 more source